Safety Labeling updates and new warnings


The manufacturer of ato-moxetine (Strattera, Lilly) was directed by FDA to revise the prescribing information for the drug to include a black box warning and additional statements that alert healthcare providers of an increased risk of suicidal thinking in children and adolescents being treated with this medication.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.